article thumbnail

Regulators questioned integrity of Pfizer/BioNTech vaccine, leaked files show

pharmaphorum

European regulators questioned the integrity of early batches of Pfizer/BioNTech’s mRNA vaccine, although the matter was resolved before approval, according to information leaked online following a cyberattack. Early commercial batches of Pfizer/BioNTech’s COVID-19 vaccine had lower than expected levels of intact mRNA.

article thumbnail

UK doctors ask for ‘urgent review’ of COVID-19 vaccine second dose delay

BioPharma Reporter

The British Medical Association (BMA), the trade union and professional body for doctors in the UK, is calling for the delay between Pfizer/BioNTech COVID-19 vaccine doses to be reduced from 12 weeks to six weeks.

Doctors 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EU regulator lifts GSK amid torrid week for company’s pipeline

pharmaphorum

The EMA has delivered some good news to GSK on a new long-acting HIV drug and vaccine for respiratory syncytial virus (RSV), in a week that saw multiple disappointments in other R&D projects. Those developments have placed much more onus on other projects – and particularly GSK’s RSV vaccine – to deliver quickly.

article thumbnail

New Trivalent Flu Vaccine for 2024/2025 and Other Insights from Leading Infectious Disease Experts Dr. Willliam Schaffner and Dr. Kelly Moore

XTalks

Influenza viruses are highly mutable, which necessitates continuous monitoring and adjustments in vaccine formulations. These seasonal outbreaks can vary in severity, depending on the circulating strains of the virus and public health preparedness, including vaccination coverage and effectiveness.

article thumbnail

US experts stress over safety of AZ’s COVID-19 vaccine

pharmaphorum

US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine trial could compromise the whole project, as the FDA weighs whether to give the go ahead for US studies to resume. The post US experts stress over safety of AZ’s COVID-19 vaccine appeared first on.

article thumbnail

Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response

pharmaphorum

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.

article thumbnail

Moderna’s COVID-19 Vaccine Candidate Shows Almost 95 Percent Effectiveness in Interim Analysis

XTalks

Moderna announced today that its highly anticipated COVID-19 vaccine candidate appears to be 94.5 The news comes shortly after Pfizer and BioNTech’s mega announcement last week of their COVID-19 vaccine having shown 90 percent efficacy in an ongoing large-scale Phase III trial. The vaccine is given in two doses.